Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Transcriptional regulation of secretory capacity by bZip transcription factors.

Fox RM, Andrew DJ.

Front Biol (Beijing). 2015 Feb 1;10(1):28-51.

2.

Changes in organelle position and epithelial architecture associated with loss of CrebA.

Fox RM, Andrew DJ.

Biol Open. 2015 Feb 13;4(3):317-30. doi: 10.1242/bio.201411205.

3.

Organ-specific gene expression: the bHLH protein Sage provides tissue specificity to Drosophila FoxA.

Fox RM, Vaishnavi A, Maruyama R, Andrew DJ.

Development. 2013 May;140(10):2160-71. doi: 10.1242/dev.092924. Epub 2013 Apr 11.

4.

The CrebA/Creb3-like transcription factors are major and direct regulators of secretory capacity.

Fox RM, Hanlon CD, Andrew DJ.

J Cell Biol. 2010 Nov 1;191(3):479-92. doi: 10.1083/jcb.201004062.

5.

An integrated strategy to study muscle development and myofilament structure in Caenorhabditis elegans.

Meissner B, Warner A, Wong K, Dube N, Lorch A, McKay SJ, Khattra J, Rogalski T, Somasiri A, Chaudhry I, Fox RM, Miller DM 3rd, Baillie DL, Holt RA, Jones SJ, Marra MA, Moerman DG.

PLoS Genet. 2009 Jun;5(6):e1000537. doi: 10.1371/journal.pgen.1000537. Epub 2009 Jun 26.

6.

The embryonic muscle transcriptome of Caenorhabditis elegans.

Fox RM, Watson JD, Von Stetina SE, McDermott J, Brodigan TM, Fukushige T, Krause M, Miller DM 3rd.

Genome Biol. 2007;8(9):R188.

7.

Cell-specific microarray profiling experiments reveal a comprehensive picture of gene expression in the C. elegans nervous system.

Von Stetina SE, Watson JD, Fox RM, Olszewski KL, Spencer WC, Roy PJ, Miller DM 3rd.

Genome Biol. 2007;8(7):R135.

8.

UNC-4 represses CEH-12/HB9 to specify synaptic inputs to VA motor neurons in C. elegans.

Von Stetina SE, Fox RM, Watkins KL, Starich TA, Shaw JE, Miller DM 3rd.

Genes Dev. 2007 Feb 1;21(3):332-46.

9.

A gene expression fingerprint of C. elegans embryonic motor neurons.

Fox RM, Von Stetina SE, Barlow SJ, Shaffer C, Olszewski KL, Moore JH, Dupuy D, Vidal M, Miller DM 3rd.

BMC Genomics. 2005 Mar 21;6:42.

10.

Lack of utility of the lysis-centrifugation blood culture method for detection of fungemia in immunocompromised cancer patients.

Creger RJ, Weeman KE, Jacobs MR, Morrissey A, Parker P, Fox RM, Lazarus HM.

J Clin Microbiol. 1998 Jan;36(1):290-3.

11.

Human M1 subunit of ribonucleotide reductase: cDNA sequence and expression in stimulated lymphocytes.

Parker NJ, Begley CG, Fox RM.

Nucleic Acids Res. 1991 Jul 11;19(13):3741. No abstract available.

13.

Mechanisms of lymphocytotoxicity induced by extracorporeal photochemotherapy for cutaneous T cell lymphoma.

Marks DI, Rockman SP, Oziemski MA, Fox RM.

J Clin Invest. 1990 Dec;86(6):2080-5.

14.
15.

Cisplatin, vinblastine, and bleomycin in inoperable non-small cell lung cancer.

Stuart-Harris R, Fox RM, Raghavan D, Coates AS, Hedley D, Levi JA, Woods RL, Tattersall MH.

Thorax. 1985 May;40(5):346-50.

16.

Relative sensitivity of human T cell subsets to deoxyadenosine toxicity.

Callard RE, Ewing TM, Fox RM.

Clin Exp Immunol. 1984 Oct;58(1):136-44.

17.
18.

Methotrexate treatment of squamous-cell head and neck cancers: dose-response evaluation.

Woods RL, Fox RM, Tattersall MH.

Br Med J (Clin Res Ed). 1981 Feb 21;282(6264):600-2.

19.

High-resolution proton nuclear magnetic resonance: application to the study of leukaemic lymphocytes.

Mountford CE, Grossman G, Gatenby PA, Fox RM.

Br J Cancer. 1980 Jun;41(6):1000-3. No abstract available.

20.

Hypercalcaemia after tamoxifen for breast cancer: a sign of tumour response?

Villalon AH, Tattersall MH, Fox RM, Woods RL.

Br Med J. 1979 Nov 24;2(6201):1329-30. No abstract available.

Supplemental Content

Loading ...
Support Center